The Volpara Health Technologies Ltd (ASX: VHT) share price went 3% on Friday after completing its acquisition.
Volpara describes itself as a ‘MedTech Software as a Software’ company that was founded in 2009 on research conducted at Oxford University. Its software is used for screening clinics to provide feedback on breast density, compression, dose and quality. Its VolparaEnterprise business provides role-specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.
Volpara has completed the acquisition of the Seattle-based MRS Systems.
The acquisition of MRS Systems increases the number of US breast clinics to which the company has access to from around 400 to over 2,000, being an increase of around 400%. Apart from the obvious immediate financial improvements this brings large amounts of additional data to optimise its analysis.
Volpara also said that it will provide stronger technical expertise, a significant increase of annual recurring revenue (ARR), accelerated sales through cross-selling opportunities and increased potential average revenue per user (ARPU) through new products.
Volpara certainly seems to be one to watch, but it has a price to match that shorter term potential. The leading growth shares in the free report below could be better priced buys for growth.
After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.
Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.
Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.
Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.
Access the free report by clicking here now. Absolutely no credit card or payment details required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.